id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-257613-o0q7hvn3	Shafiee, Abbas	Coronavirus disease 2019: A tissue engineering and regenerative medicine perspective	2020-08-21		.txt	text/plain	3427	199	43	To date, numerous studies have been conducted to evaluate the safety and efficacy of tissue engineering and regenerative medicine (TERM) products, including mesenchymal stem cells (MSCs), and their derivatives (eg, exosomes) for coronavirus infections, which could be applied for the COVID‐19. Over the COVID-19 outbreak, the funding for many TERM projects is being cut, which has a significant impact on the present and future of Current clinical trials highlight the potential benefits of stem cell therapies for COVID-19 patients. Effective multi-institutional collaboration and adequate funding from government and nongovernment sources are also needed to collect and analyze the data from ongoing and new human trials, to better understand the potential benefits of stem cell therapies for COVID-19 patients. Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial	./cache/cord-257613-o0q7hvn3.txt	./txt/cord-257613-o0q7hvn3.txt